This is a working overview of REV-ERB, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-06-01 and is reviewed periodically as new material appears.
In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.
Handling practices for SR9009 focus on minimizing degradation and contamination. The solid is generally stored desiccated at or below -20 °C, protected from light and moisture. Stock solutions are often prepared in dimethyl sulfoxide or ethanol, then aliquoted to avoid repeated freeze–thaw cycles. Aqueous solubility is low, so formulations for animal studies may require cosolvents or suspending agents. Personnel should follow institutional chemical safety procedures, because toxicological data for humans are incomplete.
Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white solid | Visual inspection is not sufficient for identity. |
| Solubility | Soluble in DMSO and ethanol | Low solubility in water. |
| Typical storage | -20 °C, desiccated, dark | Protect from repeated temperature changes. |
| Common analytical method | LC-MS or HPLC-UV | Reference standard required for comparison. |
| Common synonyms | SR9009; Stenabolic; REV-ERB agonist | Vendor naming may vary. |
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
== ABRF Executive Board == Kevin Knudtson, ABRF President, Genomics Division, University of Iowa Justine Kigenyi, Treasurer, KU Medical Center Marie Adams, Van Andel Institute Roxann Ashworth, Johns Hopkins University Kym Delventhal, Stowers Institute for Medical Research Sridar Chittur, SUNY Albany Nick Ambulos, University of Maryland School of Medicine Sue Weintraub, University of Texas Health Science Center at San Antonio Magnus Palmblad, Leiden University Medical Center Ken Schoppmann, ABRF Executive Director
Bursty: Data transfer is abrupt and does not include content such as video, audio, or other isochronous forms of data. Light: For most applications, packet sizes are limited to 256 bytes. Transmission of multiple consecutive packets may occur, but is generally avoided, if possible. Asynchronous: DASH7's main method of communication is by command–response, which by design requires no periodic network "hand-shaking" or synchronization between devices. Stealth: DASH7 devices do not need periodic beaconing to be able to respond in communication. Transitive: A DASH7 system of devices is inherently mobile or transitional. Unlike other wireless technologies, DASH7 is upload-centric, not download-centric, thus devices do not need to be managed extensively by fixed infrastructure, i.e., base stations.
SXXK motif is located at the N-terminal end of α2 helix and includes two residues that are important for the enzyme function. Ser-310 : Includes a serine nucleophile that is acylated by both peptide substrate and β-lactam antibiotics. Lys-313 : Plays an important role in providing the dense hydrogen bound network at the active site and is in distance of Ser 310, ASN-364 and the carbonyl backbone of Ser-362. SXN motif that includes Ser-362, Ser-363 and Asn-364 KTG motif that includes Lys-497, Thr-498 and Gly-499 Research also implies that adjacent regions to the active site which differ between different PBP have significant influence on the rate of β-lactam acylation rate.
== History == The black mamba (Dendroaspis polylepis) is generally considered to be one of the deadliest snakes on the planet, and is responsible for many fatalities throughout its sub-Saharan Africa range. Without treatment, the bite of a black mamba causes a 100% mortality rate. The venom of the black mamba consists of more than 28 peptides. One of these peptides is calciseptine, which makes up 2.8% of the venom. When first purified, the peptide was called protein E3, which was later changed to calciseptine by Weille et al.
Sources: en.wikipedia.org
=== Phytochemicals === Extracts of ginkgo leaves contain phenolic acids, proanthocyanidins, flavonoid glycosides, such as myricetin, kaempferol, isorhamnetin, and quercetin, and the terpene trilactones ginkgolides and bilobalides. The leaves also contain unique ginkgo biflavones, alkylphenols, and polyprenols.
During the 2014 GPU Technology Conference, Nvidia announced a port of Portal to the Nvidia Shield. The port was released on May 12, 2014. Alongside Portal 2, Portal was released on the Nintendo Switch on June 28, 2022, as part of the Portal: Companion Collection, developed by Valve and Nvidia Lightspeed Studios. Portal with RTX was announced by Nvidia during its GeForce Beyond event in September 2022. A remaster of the original, the game is intended to demonstrate the functionality of the GeForce 40 series graphics cards with real-time path tracing. Initially planned for release in November 2022, it was ultimately released December 8, 2022, as a free DLC.
For example, the latter could be reduced with hydrogen to 249CfBr2, but the former could not – this result was reproduced on individual 249BkBr3 and 249CfBr3 samples, as well on the samples containing both bromides. The intergrowth of californium in berkelium occurs at a rate of 0.22% per day and is an obstacle to studying berkelium properties. Beside a chemical contamination, 249Cf, being an alpha emitter, brings undesirable self-damage of the crystal lattice and the resulting self-heating. The chemical effect however can be avoided by performing measurements as a function of time and extrapolating the obtained results.
Sources: en.wikipedia.org
Liquid chromatography–mass spectrometry is common for identity and purity checks. High-performance liquid chromatography with ultraviolet detection can also be used. Both methods require a suitable reference standard.
The solid is usually kept desiccated at -20 °C or lower and protected from light. Stock solutions are aliquoted to limit freeze–thaw cycles. Aqueous solutions are not generally recommended for long-term storage.
Laws differ by country and by intended use. It is not an approved medicine, and many vendors sell it as a research chemical. Purchasers are responsible for confirming local restrictions.
It is a synthetic compound studied as an agonist of REV-ERB nuclear receptors. It is not an approved medicine and has mainly been examined in laboratory and animal research.